Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
HOOK

HOOK - Hookipa Pharma Inc Stock Price, Fair Value and News

$1.050.00 (0.00%)
Market Closed

77/100

HOOK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

77/100

HOOK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HOOK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HOOK Price Action

Last 90 days

18.0%

Trailing 12 Months

-19.2%

HOOK RSI Chart

HOOK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HOOK Valuation

Market Cap

10.6M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

1.15

EV/EBITDA

0.42

Price/Free Cashflow

-0.2

HOOK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HOOK Fundamentals

HOOK Revenue

HOOK Earnings

HOOK Profitability

Free Cashflow Yield

-492.88%

HOOK Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20259.4M000
202453.6M52.2M50.0M43.9M
202316.0M15.9M20.6M20.1M
202214.6M12.0M10.3M14.2M
202121.2M19.9M19.7M18.4M
202013.4M16.0M18.0M19.6M
20199.9M13.3M13.4M11.9M
20180007.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Hookipa Pharma Inc

HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
 CEO
 WEBSITEhookipapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES156

Hookipa Pharma Inc Frequently Asked Questions

HOOK is the stock ticker symbol of Hookipa Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Mar 12 2026, market cap of Hookipa Pharma Inc is 10.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Mar 12 2026, HOOK's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 1.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOOK PE ratio will change depending on the future growth rate expectations of investors.